TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07482787: Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Sponsor: Paradigm Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 80 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT07482787 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07482787 Rescue Dossier →